Clinical Trial Update: A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

View source ↗

Summary

Clinical trial registry entry evaluating MEK inhibitor–based combination therapy for KRAS G12R-altered pancreatic ductal adenocarcinoma. Recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• MEK inhibitor-based combination therapy

Snippet

Sponsor: Mandana Kamgar, MD | Conditions: Pancreatic Ductal Adenocarcinoma | Status: RECRUITING